Can I read The PARP1 Selective Inhibitor Saruparib (AZD5305) Elicits Potent and Durable Antitumor Activity in Patient Derived Associated Cancer Models on EtoBox?

The PARP1 Selective Inhibitor Saruparib (AZD5305) Elicits Potent and Durable Antitumor Activity in Patient Derived Associated Cancer Models by Luis Paez is a document available to read on EtoBox.

What is The PARP1 Selective Inhibitor Saruparib (AZD5305) Elicits Potent and Durable Antitumor Activity in Patient Derived Associated Cancer Models about?

The study evaluates the PARP1 selective inhibitor saruparib (AZD5305) and its antitumor efficacy in patient-derived cancer models with BRCA1/2 mutations. AZD5305 demonstrated superior antitumor activity compared to the first-generation PARP inhibitor olaparib, achieving a higher complete response rate and longer progression-free survival. The findings suggest that AZD5305 could be a promising therapeutic option for patients with homologous recombination deficiency in various cancers.

Author

Luis Paez

Language

EN